Log in or Sign up for Free to view tailored content for your specialty!
Optics News
OCS-05 meets safety, efficacy endpoints in acute optic neuritis trial
OCS-05 met safety and efficacy endpoints in the treatment of acute optic neuritis in a phase 2 trial, according to a press release from Oculis.
Top red light therapy stories of 2024 report potential, caution
Red light therapy, a relatively new treatment option, has made waves recently as studies investigate its potential for controlling myopia in children.
Low-level red light therapy superior to ortho-K for myopia control at 1 year
Low-level red light therapy was superior to orthokeratology lenses at slowing myopia progression in children in the first year of treatment, though the difference was not significant in the second year, according to study results.
Log in or Sign up for Free to view tailored content for your specialty!
Top FDA stories of 2024: New technology, potentially contaminated eye drops
Every year Healio covers a wide range of optometry-related news from the FDA, and 2024 was no exception.
Top contact lens stories of 2024: Innovation, purchasing options
This year saw several innovations in contact lenses, including tinted lenses for athletes and the new Clariti multifocal lens by CooperVision.
VIDEO: Precision7 ‘meets right in the middle’ of patient demands, OD concerns
INDIANAPOLIS — Alcon’s new Precision7 1-week contact lens strikes the balance between eye care providers’ preference for daily disposable lenses and patients’ desire for a more cost-effective solution, according to Kristen Brotherson.
VIDEO: High-energy visible light filters reduce glare disability, discomfort
INDIANAPOLIS — High-energy visible light-filtering multifocal lenses reduced glare disability and discomfort without affecting color perception, according to research presented at Academy 2024.
Aceclidine-based miotic improves both near, distance vision
INDIANAPOLIS — An aceclidine-based miotic may improve both near and distance vision in presbyopic patients as a result of its pupil selectivity, according to research presented at Academy 2024.
Study of atropine-based myopia treatment fails to meet primary efficacy endpoint
Eyenovia’s phase 3 CHAPERONE study evaluating low-dose atropine delivered via the company’s Optejet dispenser is not meeting its primary endpoint of a less than 0.50 D progression in visual acuity over 3 years, according to a press release.
VIDEO: Understand normal myopia progression, axial elongation for better control
INDIANAPOLIS — To better manage patients with myopia, optometrists must understand normal myopia progression and axial elongation, as well as trends in treatment efficacy, according to a speaker at Academy 2024.
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read